International Clinical Neuroscience Journal

Vol. 6 No. 4 (2019)

Effect of Nanomicelle Curcumin on Quality of Life and Sleep in Patients With Parkinson’s Disease: A Double-Blind, Randomized, and Placebo-Controlled Trial

International Clinical Neuroscience Journal, Vol. 6 No. 4 (2019), 23 September 2019 , Page 140-145

Abstract

Background: Considering the evidence indicating the neuronal protective effects of curcumin in previous studies, this double-blind, randomized, placebo-controlled, and parallel-group trial was aimed at exploring the possible nanomicelle curcumin (SinaCurcumin®, nano-micellar soft gel)-mediated impact on sleep, fatigue, and quality of life (QoL) in patients with Parkinson’s disease (PD).
Methods: A sample of 50 PD patients were recruited and randomly divided into experimental (25) and control groups (25). Sleep quality, fatigue, and QoL were assessed based on the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and the Parkinson’s Disease Questionnaire–39 (PDQ-39), respectively, at the beginning and the end of the study. The groups were treated for three months by 80 mg of nano-micellar soft gel twice a day.
Results: Nanomicelle curcumin significantly increased sleep quality and QoL compared with placebo (P values = 0.0001 and 0.0002, respectively) in PD patients. This significant difference has not influenced by the duration of the disease, the severity of disease progression (Hoehn & Yahr scale), and the cumulative dose of levodopa. This supplement did not have a significant effect on the fatigue severity of patients compared to placebo.
Conclusion: It has proposed that the nanomicelle curcumin can be used to improve sleep quality and QoL in PD patients.

Keywords:
  • Parkinson’s disease
  • Nanomicelle curcumin
  • Sleep quality
  • Fatigue severity
  • Quality of life.

How to Cite

1.
Maghbooli M, Safarnejad B, Mostafavi H, Mazloomzadeh S, Ghoreishi A. Effect of Nanomicelle Curcumin on Quality of Life and Sleep in Patients With Parkinson’s Disease: A Double-Blind, Randomized, and Placebo-Controlled Trial. Int Clin Neurosci J [Internet]. 2019 Sep. 23 [cited 2025 Apr. 26];6(4):140-5. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/26302

References

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896-912. doi: 10.1016/s0140- 6736(14)61393-3.

Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139 Suppl 1:318-24. doi: 10.1111/jnc.13691.

Opara JA, Brola W, Leonardi M, Blaszczyk B. Quality of life in Parkinson’s disease. J Med Life. 2012;5(4):375-81.

Stoker TB, Torsney KM, Barker RA. Emerging Treatment Approaches for Parkinson’s Disease. Front Neurosci. 2018;12:693. doi: 10.3389/fnins.2018.00693.

Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol. 2007;595:197-212. doi: 10.1007/978-0-387-46401-5_8.

Al-Karawi D, Al Mamoori DA, Tayyar Y. The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials. Phytother Res. 2016;30(2):175-83. doi: 10.1002/ptr.5524.

Bitu Pinto N, da Silva Alexandre B, Neves KR, Silva AH, Leal LK, Viana GS. Neuroprotective Properties of the Standardized Extract from Camellia sinensis (Green Tea) and Its Main Bioactive Components, Epicatechin and Epigallocatechin Gallate, in the 6-OHDA Model of Parkinson’s Disease. Evid Based Complement Alternat Med. 2015;2015:161092. doi: 10.1155/2015/161092.

Dai F, Chen WF, Zhou B, Yang L, Liu ZL. Antioxidative effects of curcumin and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Phytother Res. 2009;23(9):1220-8. doi: 10.1002/ptr.2517.

Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs. 2012;21(8):1123-40. doi: 10.1517/13543784.2012.693479.

Daverey A, Agrawal SK. Curcumin alleviates oxidative stress and mitochondrial dysfunction in astrocytes. Neuroscience. 2016;333:92-103. doi: 10.1016/j.neuroscience.2016.07.012.

Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, et al. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br J Nutr. 2016;115(3):449-65. doi: 10.1017/ s0007114515004687.

Kumar TP, Antony S, Gireesh G, George N, Paulose CS. Curcumin modulates dopaminergic receptor, CREB and phospholipase C gene expression in the cerebral cortex and cerebellum of streptozotocin induced diabetic rats. J Biomed Sci. 2010;17:43. doi: 10.1186/1423-0127-17-43.

Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85-94. doi: 10.1016/j.tips.2008.11.002.

Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer’s disease. CNS Neurosci Ther. 2010;16(5):285-97. doi: 10.1111/j.1755-5949.2010.00147.x.

Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 2012;69(1):65-70. doi: 10.1007/ s00280-011-1673-1.

Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5. doi: 10.1248/bpb.34.660.

Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N, et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. J Nutr Sci Vitaminol (Tokyo). 2015;61(1):37- 44. doi: 10.3177/jnsv.61.37.

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

Fereshtehnejad SM, Hadizadeh H, Farhadi F, Shahidi GA, Delbari A, Lokk J. Reliability and validity of the persian version of the fatigue severity scale in idiopathic Parkinson’s disease patients. Parkinsons Dis. 2013;2013:935429. doi: 10.1155/2013/935429.

Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241-8.

Nojomi M, Mostafavian Z, Shahidi GA, Jenkinson C. Quality of life in patients with Parkinson’s disease: Translation and psychometric evaluation of the Iranian version of PDQ-39. J Res Med Sci. 2010;15(2):63-9.

Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140- 4. doi: 10.1016/j.sleep.2016.01.016.

Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K. Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology. 2009;214(1):33-9. doi: 10.1016/j. imbio.2008.04.003.

Huang WC, Chiu WC, Chuang HL, Tang DW, Lee ZM, Wei L, et al. Effect of curcumin supplementation on physiological fatigue and physical performance in mice. Nutrients. 2015;7(2):905-21. doi: 10.3390/nu7020905.

Ledda A, Belcaro G, Feragalli B, Hosoi M, Cacchio M, Luzzi R, et al. Temporary kidney dysfunction: Robuvit(R) supplementation in initial, transient kidney insufficiency and micro-macro albuminuria. Panminerva Med. 2018;60(2):60- 4. doi: 10.23736/s0031-0808.18.03420-1.

Pandaran Sudheeran S, Jacob D, Natinga Mulakal J, Gopinathan Nair G, Maliakel A, Maliakel B, et al. Safety, Tolerance, and Enhanced Efficacy of a Bioavailable Formulation of Curcumin With Fenugreek Dietary Fiber on Occupational Stress: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. J Clin Psychopharmacol. 2016;36(3):236-43. doi: 10.1097/ jcp.0000000000000508.

  • Abstract Viewed: 499 times
  • PDF Downloaded: 503 times

Download Statastics